Deepa Philip
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1659614105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,764, more than ten times the $261 reported in 2019.
Across 158 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$372
- Medtronic$358
- Tandem Diabetes Care, Inc.$296
- Amgen$291
- Madrigal Pharmaceuticals$279
- Corcept Therapeutics$231
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,00499%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 16 | $372 |
| Medtronic(2 entities) | 5 | $358 |
| Tandem Diabetes Care, Inc. | 11 | $296 |
| Amgen | 11 | $291 |
| Madrigal Pharmaceuticals | 8 | $279 |
| Corcept Therapeutics | 11 | $231 |
| Sanofi-aventis U.S. LLC | 10 | $220 |
| AstraZeneca(2 entities) | 5 | $204 |
| Ascendis Pharma Endocrinology Inc | 2 | $146 |
| Dexcom, Inc. | 8 | $145 |
| Radius Health, Inc. | 6 | $144 |
| Boehringer Ingelheim | 8 | $136 |
| Abbott | 7 | $135 |
| Lilly USA, LLC | 6 | $112 |
| Kyowa Kirin, Inc. | 4 | $108 |
| BETA Bionics, Inc. | 6 | $107 |
| Novo Nordisk | 5 | $101 |
| AbbVie | 5 | $92 |
| Mannkind Corporation | 3 | $90 |
| Sequel Med Tech, LLC | 4 | $89 |
| Insulet Corporation | 3 | $72 |
| Cequr Corporation | 2 | $71 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Acella Pharmaceuticals, LLC | 2 | $43 |
| Antares Pharma, Inc. | 2 | $40 |
| Globus Medical | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Bayer | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Averitas Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$188
- Minimed 670G System$136
- EVENITY$130
- FARXIGA$125
- RECORLEV$118
- Yorvipath$117
How this compares
$4,047 in reported general payments places this provider in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $143,519 |
| MounjaroTirzepatide | 87 | $95,632 |
| TrulicityDulaglutide | 77 | $91,659 |
| Somatuline DepotLanreotide Acetate | 12 | $72,540 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $59,340 |
| JardianceEmpagliflozin | 44 | $43,905 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $38,813 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $32,696 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $26,944 |
| RybelsusSemaglutide | 16 | $25,440 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $25,243 |
| FarxigaDapagliflozin Propanediol | 24 | $23,911 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $19,433 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $18,057 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $14,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $112 | $191,628179 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $101 | $175,571157 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $136 | $70,84967 claims |
| AstraZenecaFarxiga | $204 | $23,91124 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $220 | $19,43313 claims |
| AbbVieSynthroid | $92 | $4,25771 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $2,568248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.